key: cord-0848074-rb5j4lon
authors: Murphy, Sean M.; Yoder, James; Pathak, Jyotishman; Avery, Jonathan
title: Healthcare Utilization Patterns among Persons Who Use Drugs During the COVID-19 Pandemic
date: 2020-10-21
journal: J Subst Abuse Treat
DOI: 10.1016/j.jsat.2020.108177
sha: e17472c1bb7e7f5c368be30be45afead4758635f
doc_id: 848074
cord_uid: rb5j4lon

Persons with drug use disorders are an underserved and stigmatized population, and the COVID-19 pandemic could exacerbate these issues. The discussion around those with drug use disorders in the midst of the pandemic has focused on the need to ensure uninterrupted treatment access; however, very few in this population actually receive treatment, and retention is a substantial issue among those who do. Evidence from other chronic conditions suggests persons at high risk for severe COVID-19 complications are foregoing care due to fear of contracting the virus. Persons with drug use disorders tend to fall into this high-risk category, and thus may be avoiding healthcare facilities. Our data suggest this is true. If so, adverse outcomes, and increased severity of use disorders and associated health complications, could become prevalent. Clinicians should identify persons with drug use disorders who may be foregoing treatment, and engage them using methods that minimize the risk of COVID-19 transmission.

The COVID-19 pandemic has created novel healthcare and behavioral concerns; among them are questions regarding changes in healthcare utilization patterns, and the consequences of these changes, among persons with drug use disorders. According to the most recent national figures, 8.1 million U.S. persons had a drug use disorder in 2018 (Substance Abuse and Mental Health Services Administration, 2019a), and 67,367 died of a drug overdose (Centers for Disease Control and Prevention, 2020a) . Persons with drug use disorders are already an underserved and stigmatized population and the addition of the COVID-19 pandemic has the potential to exacerbate these issues.

Given the commonality of access barriers to evidence-based treatment for drug use disorders in the pre-COVID landscape, much of the discussion around persons with drug use disorders in the midst of the pandemic has focused on the need to ensure uninterrupted treatment access, and the widely praised responses from the Drug Enforcement Administration (DEA), Substance Abuse and Mental Health Services Administration (SAMHSA), and others (American Society of Addiction Medicine, 2020). For example, authorized practitioners and opioid treatment providers (OTPs) can continue to treat patients with buprenorphine via telehealth, including via telephone due to the temporary relaxation of Health Insurance Portability and Accountability Act (HIPAA) regulatory requirements by the U.S. Department of Health & Human Services (HHS) Office of Civil Rights. OTPs can also provide unsupervised take-home methadone to existing patients via telehealth/telephone. Additionally, Medicare has expanded the J o u r n a l P r e -p r o o f Journal Pre-proof range of telehealth services it will cover, and increased the rate at which it covers them, and the HHS Secretary has waived the requirement that providers hold a license in the same state as the person they are treating. Authorized practitioners are now allowed to forgo the in-person physical examination for new patients with opioid use disorder that is required prior to initiating buprenorphine treatment; new patients who prefer methadone must still be seen in-person prior to initiation. However, only 9% of persons with a drug use disorder received specialty treatment in 2018 (Substance Abuse and Mental Health Services Administration, 2019a), and among persons who do initiate treatment, many have difficulty adhering to that treatment, due to the chronic, relapsing nature of substance use disorders. Research has established that no, or inadequate, treatment for drug use disorder is associated with increased utilization of high-cost healthcare resources, particularly those of an emergent nature, which often culminate in an inpatient stay (Gryczynski et al., 2016; Murphy & Polsky, 2016) . For example, more than 270,000 people received treatment for a drug use disorder in the emergency room in 2018 (Substance Abuse and Mental Health Services Administration, 2019a).

Healthcare visits by persons with a drug use disorder can and should serve as critical touchpoints with the system, offering providers the opportunity to connect these patients to evidence-based treatment. The most recent data on admissions to facilities that receive government funds for treatment of substance use disorders indicate that 11% (n=113,738) of admissions for a primary substance of opioids or stimulants were referred from a healthcare provider specializing in the treatment of substance use disorder, and another 5% (n=52,504) were referred from a healthcare provider other than one specializing in the treatment of substance use disorder (Substance Abuse and Mental Health Services Administration, 2019b).

Journal Pre-proof

A major response to the COVID-19 pandemic has been the strong encouragement or requirement of social distancing to prevent the spread of the virus. This is particularly true for persons who face an increased risk of severe COVID-19 complications, including mortality (Centers for Disease Control and Prevention, 2020b). Consequently, the manner in which many individuals access the healthcare system has rapidly transitioned from in-person physical care to virtual visits, where possible, while willingness to seek medical care may have declined in situations where virtual visits are not feasible.

To understand the current situation regarding healthcare utilization patterns among persons with a drug use disorder during COVID-19, it may be helpful to see how healthcare utilization patterns for other medical conditions have changed. Garcia et al. (2020) reviewed 9 high-volume cardiac catheterization laboratories in the U.S. following the emergence of COVID-19 and found a 38% decrease (p<0.001) in ST-Elevation Myocardial Infarction (STEMI) activations, which is similar to the 40% reduction reported in Spain (Rodríguez-Leor et al., 2020) .

Anecdotal evidence suggests that this reduction is due in large part to fear of entering healthcare facilities and contracting COVID-19, given their increased risk of severe COVID-19 complications (McFarling, 2020) . Similar evidence exists for stroke, where one study found U.S. patients seeking care for stroke dropped 39% following the onset of COVID-19 (Kansagra, providers can continue to work together to develop tools that utilize "real-world" data from electronic health records (EHRs) to aid in the recognition and phenotyping of persons with drug use disorder (Afshar et al., 2019; Chartash et al., 2019; Sanchez-Roige & Palmer, 2019; Sharma et al., 2020) , which would allow providers to better identify both new and existing patients.

Providers can also continue to develop methods to improve identification and linkage of persons with drug use disorder within their current environment, such as linking EHR data with information from statewide prescription drug monitoring programs (Holmgren & Apathy, 2020) .

Subtypes in patients with opioid misuse: A prognostic enrichment strategy using electronic health record data in hospitalized patients

Issue brief: Reports of increases in opioid-related

People Who Are at Higher Risk for Severe Illness

Identifying Opioid Use Disorder in the Emergency Department: Multi-System Electronic Health Record-Based Computable Phenotype Derivation and Validation Study

Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic

Understanding patterns of high-cost health care use across different substance user groups

Evaluation of Prescription Drug Monitoring Program Integration With Hospital Electronic Health Records by US County-Level Opioid Prescribing Rates

Collateral Effect of Covid-19 on Stroke Evaluation in the United States

Shadow of Pandemic, U.S. Drug Overdose Deaths Resurge to Record. The New York Times

Where are all our patients?": Covid phobia is keeping people with serious heart symptoms away from ERs

Economic evaluations of opioid use disorder interventions: a systematic review

Impacto de la pandemia de COVID-19 sobre la actividad asistencial en cardiología intervencionista en España

Electronic health records are the next frontier for the genetics of substance use disorders

Publicly available machine learning models for identifying opioid misuse from the clinical notes of hospitalized patients

National Survey on Drug Use and Health (NSDUH)

Treatment Episode Data Set (TEDS): 2017. U.S. Department of Health and Human Services (HHS)

Cries for help": Drug overdoses are soaring during the coronavirus pandemic

We are grateful to Danielle Ryan, MPH for her assistance in finalizing the manuscript and preparing it for submission.

J o u r n a l P r e -p r o o f